Recommendations for laboratory testing of UK patients with acute myeloid leukaemia

Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene‐CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT)

“…2 The 2022 British Society for Haematology (BSH) good practice recommendations for laboratory testing in AML stress the identification of familial predisposition to haematological malignancy enabling referral to clinical genetics and wider testing when considering a related-donor allogeneic transplant but do not include details on donor selection. 29 Recommendations reflect consensus obtained from in-meeting polling and subsequent discussion combined with practical guidance to achieve these consensus aims. For clarity each recommendation is mapped to in-meeting polling, 1 in meeting discussion 2 or post-meeting practical considerations.…”

“…The 2022 European Leukaemia Net AML guidelines recommend testing for germline risk alleles early in management but highlight the lack of data on most variants except those in RUNX1 and CEBPA 2 . The 2022 British Society for Haematology (BSH) good practice recommendations for laboratory testing in AML stress the identification of familial predisposition to haematological malignancy enabling referral to clinical genetics and wider testing when considering a related‐donor allogeneic transplant but do not include details on donor selection 29 …”

Association of genetic predisposition studies in CYP1A1 polymorphism studies in acute myeloid leukemia

“…The treatment is still challenging among AML patients with survival rate of 30 % patients during the half-decades ( Naldini et al, 2023 ). Blood, bone marrow, and, if necessary, cerebrospinal fluid must undergo a variety of laboratory examinations, including morphological, immunophenotypic, and genetic assessment, in order to arrive at a definitive diagnosis of AML ( Mehta et al, 2023 ). Classification of AML is an ongoing endeavor necessary for effective disease treatment ( McCarter et al, 2023 ).…”

Correction to “Recommendations for laboratory testing of UK patients with acute myeloid leukaemia”

“…In the Acknowledgements section of the published article, 1 Professor Barbara Bain was incorrectly mentioned as a Dame. The first sentence should read as follows:…”